TY - JOUR
T1 - Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers
AU - Zaaijer, Leendert H.
AU - van Doorn, Helena C.
AU - Mourits, Marian J. E.
AU - van Beurden, Marc
AU - de Hullu, Joanne A.
AU - Adank, Muriel A.
AU - van Lonkhuijzen, Luc R. C. W.
AU - Vasen, Hans F. A.
AU - Slangen, Brigitte F. M.
AU - Gaarenstroom, Katja N.
AU - Zweemer, Ronald P.
AU - Vencken, Peggy M. L. H.
AU - Seynaeve, Caroline
AU - Kriege, Mieke
PY - 2016/11/8
Y1 - 2016/11/8
N2 - Background: It is unknown whether a history of breast cancer (BC) affects the outcome of BRCA1/2-associated epithelial ovarian cancer (EOC). This was investigated in the current analysis. Methods: We included 386 BRCA1/2-associated EOC patients diagnosed between 1980 and 2015. Progression-free survival (PFS), progression-free interval (PFI), overall survival (OS) and ovarian cancer-specific survival (OCSS) were compared between EOC patients with and without previous BC. Results: BRCA-associated EOC patients with, vs without, a BC history had a significantly worse PFS and PFI (multivariate hazard ratio (HRmult) 1.47; 95% confidence interval (CI) 1.03-2.08 and HRmult 1.43; 95% CI 1.01-2.03), and a non-significantly worse OS (HRmult 1.15; 95% CI 0.84-1.57) and OCSS (HRmult 1.18; 95% CI 0.85-1.62). Ovarian cancer-specific survival was significantly worse for the subgroup treated with adjuvant chemotherapy for BC (HRmult 1.99; 95% CI 1.21-3.31). Conclusions: Our results suggest that BRCA1/2-associated EOC patients with a previous BC have a worse outcome than EOC patients without BC, especially when treated with adjuvant chemotherapy.
AB - Background: It is unknown whether a history of breast cancer (BC) affects the outcome of BRCA1/2-associated epithelial ovarian cancer (EOC). This was investigated in the current analysis. Methods: We included 386 BRCA1/2-associated EOC patients diagnosed between 1980 and 2015. Progression-free survival (PFS), progression-free interval (PFI), overall survival (OS) and ovarian cancer-specific survival (OCSS) were compared between EOC patients with and without previous BC. Results: BRCA-associated EOC patients with, vs without, a BC history had a significantly worse PFS and PFI (multivariate hazard ratio (HRmult) 1.47; 95% confidence interval (CI) 1.03-2.08 and HRmult 1.43; 95% CI 1.01-2.03), and a non-significantly worse OS (HRmult 1.15; 95% CI 0.84-1.57) and OCSS (HRmult 1.18; 95% CI 0.85-1.62). Ovarian cancer-specific survival was significantly worse for the subgroup treated with adjuvant chemotherapy for BC (HRmult 1.99; 95% CI 1.21-3.31). Conclusions: Our results suggest that BRCA1/2-associated EOC patients with a previous BC have a worse outcome than EOC patients without BC, especially when treated with adjuvant chemotherapy.
KW - BRCA mutation
KW - breast cancer
KW - ovarian cancer
KW - survival
KW - chemotherapy
U2 - 10.1038/bjc.2016.333
DO - 10.1038/bjc.2016.333
M3 - Article
C2 - 27755534
SN - 0007-0920
VL - 115
SP - 1174
EP - 1178
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 10
ER -